Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 178-185

  Chen, Wei ^a   Tang, Huoling ^b   Liu, Hongying ^a   Long, Long ^a   Gong, Zehui ^a   Zheng, Jianquan ^a   Chi, Mugen ^a   Xie, Yunde ^a   Zheng, Zhibing ^a   Li, Song ^a   Wang, Lili ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Ca2+ i; Antagonist; CAMP; Cannabinoid CB1 receptor; Diet induced obesity

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL N (PYRIDIN 3 METHYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; MJ 15; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; BRAIN CELL; CALCIUM CELL LEVEL; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; FOOD INTAKE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTESTINE MOTILITY; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SMALL INTESTINE; WEIGHT GAIN;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; EATING; HIPPOCAMPUS; MALE; MICE; MICE, INBRED ICR; OBESITY; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RODENTIA; TIME FACTORS;

EID: 77953239310     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.040     Document Type: Article

References (40)

1. Bidaut-Russell M., Devane W.A., Howlett A.C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 1990, 55:21-26.
2. Chen R.Z., Frassetto A., Lao J.Z., Huang R.R.C., Xiao J.C., Clements M.J., Walsh T.F., Hale J.J., Wang J.Y., Tong X.C., Fong T.M. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur. J. Pharmacol. 2008, 584:338-342.
3. Childers S.R., Deadwyler S.A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 1996, 52:819-827.
4. Childers S.R., Pacheco M.A., Bennett B.A., Edwards T.A., Hampson R.E., Mu J., Deadwyler S.A. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 1993, 59:27-50.
5. Colombo G., Agabio R., Lobina C., Reali R., Gessa G.L. Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol. 1998, 344:67-69.
6. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., Pagotto U., Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab Disord. 2003, 27:289-301.
7. Croci T., Manara L., Aureggi G., Guagnini F., Rinaldi-Carmona M., Maffrand J.P., Le F.G., Mukenge S., Ferla G. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol. 1998, 125:1393-1395.
8. de Kloet A.D., Woods S.C. Minireview: endocannabinoids and their receptors as targets for obesity therapy. Endocrinology 2009, 150:2531-2536.
9. Di Marzo V., Szallasi A. Rimonabant in rats with a metabolic syndrome: good news after the depression. Br. J. Pharmacol. 2008, 154:915-917.
10. Drysdale A.J., Ryan D., Pertwee R.G., Platt B. Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 2006, 50:621-631.
11. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 1992, 42:838-845.
12. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 1998, 284:291-297.
13. Fong T.M., Guan X.M., Marsh D.J., Shen C.P., Stribling D.S., Rosko K.M., Lao J., Yu H., Feng Y., Xiao J.C., Van der Ploeg L.H., Goulet M.T., Hagmann W.K., Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Francis B., Strack A.M., MacIntyre D.E., Shearman L.P. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 2007, 321:1013-1022.
14. Fremming B.A., Boyd S.T. Taranabant, a novel cannabinoid type 1 receptor inverse agonist. Curr. Opin. Invest. Drugs 2008, 9.
15. Gardner E.L., Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 1998, 5:502-533.
16. Griffith D.A., Hadcock J.R., Black S.C., Iredale P.A., Carpino P.A., DaSilva-Jardine P., Day R., DiBrino J., Dow R.L., Landis M.S., O'Connor R.E., Scott D.O. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperi dine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J. Med. Chem. 2009, 52:234-237.
17. Grotenhermen F. Cannabinoids. Curr. Drug Targets. CNS. Neurol. Disord. 2005, 4:507-530.
18. Hildebrandt A.L., Kelly-Sullivan D.M., Black S.C. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur. J. Pharmacol. 2003, 462:125-132.
19. Horswill J.G., Bali U., Shaaban S., Keily J.F., Jeevaratnam P., Babbs A.J., Reynet C., In P.W.K. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br. J. Pharmacol. 2007, 152:805-814.
20. Irwin N., Hunter K., Frizzell N., Flatt P.R. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Eur. J. Pharmacol. 2008, 581:226-233.
21. Janero D.R., Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert. Opin. Emerg. Drugs 2009, 14:43-65.
22. Landi M., Croci T., Rinaldi-Carmona M., Maffrand J.P., Le F.G., Manara L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur. J. Pharmacol. 2002, 450:77-83.
23. Lauckner J.E., Hille B., Mackie K. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19144-19149.
24. Lichtman A.H., Martin B.R. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 1996, 126:125-131.
25. Mercer J.G., Archer Z.A. Diet-induced obesity in the Sprague-Dawley rat: dietary manipulations and their effect on hypothalamic neuropeptide energy balance systems. Biochem. Soc. Trans. 2005, 33:1068-1072.
26. 2+ signals in cerebellar granule neurons in culture. J. Neurosci. 1999, 19:8765-8777.
27. Patricia H.R. Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists. Drug Dev. Res. 2009, 70:585-600.
28. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 1997, 74:129-180.
29. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CBI receptors. Life Sci. 2005, 76:1307-1324.
30. Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., Corbett A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 1992, 105:980-984.
31. Pinto L., Capasso R., Di C.G., Izzo A.A. Endocannabinoids and the gut. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:333-341.
32. Ravinet T.C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol 2003, 284:R345-R353.
33. Rinaldi-Carmona M., Calandra B., Shire D., Bouaboula M., Oustric D., Barth F., Casellas P., Ferrara P., Le F.G. Characterization of two cloned human CB1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther. 1996, 278:871-878.
34. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D., Perio A., Poncelet M., Maruani J., Arnone M., Finance O., Soubrie P., Le Fur G. SR147778 [5-(4-bromophenyl)-1-(2, 4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004, 310:905-914.
35. Shearman L.P., Stribling D.S., Camacho R.E., Rosko K.M., Wang J.Y., Tong S., Feng Y., Marsh D.J., Yu H., Guan X.M., Spann S.K., MacNeil D.J., Fong T.M., Metzger J.M., Goulet M.T., Hagmann W.K., Plummer C.W., Finke P.E., Mills S.G., Shah S.K., Truong Q., Van der Ploeg L.H.T., Maclntyre D.E., Strack A.M. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents. Eur. J. Pharmacol. 2008, 579:215-224.
36. 2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 1996, 229:58-64.
37. Vemuri V.K., Janero D.R., Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav. 2008, 93:671-686.
38. Venance L., Sagan S., Giaume C. (R)-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes. Pflugers Arch. 1997, 434:147-149.
39. Wellman P.J., Jones S.L., Miller D.K. Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat. Pharmacol. Biochem. Behav. 2003, 75:103-114.
40. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994, 63:637-652.